Columbia University scientists have found that serotonin may accelerate the progression of degenerative mitral regurgitation in certain individuals [1].
This discovery is significant because it identifies a biological pathway where mood-regulating chemicals and common medications could influence the physical deterioration of heart valves. For high-risk patients, this could mean a faster transition from manageable symptoms to severe heart failure.
Researchers at Columbia University said scientists have uncovered evidence that serotonin, the chemical best known for regulating mood, may also speed the progression of a common heart valve disease in some people [1]. The study focuses on degenerative mitral regurgitation, a condition where the heart's mitral valve does not close tightly, allowing blood to flow backward [1].
The findings highlight a specific intersection of pharmacology and genetics. A lead researcher said the research suggests that patients with degenerative mitral regurgitation who take SSRI antidepressants and carry a specific genetic variant may develop severe valve damage sooner [1].
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for depression and anxiety by increasing serotonin levels in the brain [1]. However, this study indicates that the chemical may have unintended effects on the structural integrity of the heart valve in susceptible populations.
Because the disease progresses more rapidly in these individuals, they may face a higher urgency for medical intervention. A researcher said this could lead to patients potentially requiring surgery at a younger age [1].
The research was uncovered in July 2026, providing a new lens for clinicians to evaluate the long-term cardiovascular risks associated with certain psychiatric medications and genetic markers [1].
“Serotonin, the chemical best known for regulating mood, may also speed the progression of a common heart valve disease.”
This research introduces a personalized medicine approach to cardiology by linking psychiatric medication use and genetic predisposition to physical heart valve decay. It suggests that for a subset of the population, the systemic increase of serotonin via SSRIs may act as a catalyst for degenerative mitral regurgitation, potentially shifting the timeline for surgical intervention and requiring more frequent cardiac monitoring for patients on these medications.
